Hydrogen sulfide donors or related derivatives are the future medicines of renal diseases | ||||
| Egyptian Pharmaceutical Journal | ||||
| Volume 16, Issue 1, January 2017, Page 1-7 PDF (130.25 K) | ||||
| DOI: 10.4103/1687-4315.205827 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Marwan S.M. Al-Nimer | ||||
| Abstract | ||||
Hydrogen sulfide (HS) is one of the three gasotransmitters that possess anti-inflammatory, antiapoptotic, and antioxidant properties. It maintains the function of the kidney through its effect on the glomeruli and the renal transport system. Literature review using PubMed, Excerpta Medica database (EMBASE), Google scholar, and Cochrane review revealed that HS donors are introduced as exogenous HS and have been found to target many organs in in-vitro and in-vivo studies. This review provides the main research that was performed on the HS donors in the context of kidney disease. Exogenous HS supplementation can be administered in different therapeutic areas promising therapeutic strategy in the setting of kidney diseases. Therefore, suitable pharmaceutical preparations of HS donors are necessary to be launched in the markets for the prevention and treatment of acute/chronic renal diseases. | ||||
| Keywords | ||||
| Free radicals; hydrogen sulfide donors; ionic channels; Kidney diseases | ||||
|
Statistics Article View: 25 PDF Download: 18 |
||||
